Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Moderna Inc MRNA

Healthcare Biotechnology
Moderna, Inc. is a biotechnology company. The Company is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases, independently and with its strategic collaborators. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. Its diverse development pipeline consists of 45 therapeutic and vaccine programs, nine of which are in late-stage development. Its products include COVID-19 vaccines (mRNA-1273/Spikevax, next-generation mRNA-1283), RSV vaccine (mRNA-1345), Seasonal influenza vaccines (mRNA-1010, mRNA-1011, mRNA-1012, mRNA-1020 and mRNA-1030), Combination vaccines (mRNA-1083, mRNA-1230, mRNA-1045 and mRNA-1365), CMV vaccine (mRNA-1647), EBV vaccine (mRNA-1189 and mRNA-1195) and others.


NDAQ:MRNA - Post by User

Moderna Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(0)
•••
Post by PressReleaseon Sep 01, 2024 7:02am
3 Views
Post# 36204453

New Press Release - MRNA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Moderna, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

New Press Release - MRNA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Moderna, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
NEW YORK CITY, NY / ACCESSWIRE / September 1, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Moderna, Inc. ("Moderna" or "the Company") (NASDAQ:MRNA) and certain of its officers.Class...read article.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities